Stockley’s Drug Interactions is the most indispensable source of drug interaction information available.
It provides expertly authored advice on managing drug interactions, and will quickly and reliably help you decide your best course of action.
Sales and UpgradesContent Updates
With over 4,500 detailed records, access drug-drug, drug-herb, drug-food interactions and much more
Featuring a concise summary at the start of each record, you can also discover the clinical evidence, mechanism, importance and management of each interaction
Contains detailed, fully referenced and international information with an unrivalled depth of content
*based on average data in the last 12 months
Stockley’s Drug Interactions update with new and revised monographs.
There are 6 new monographs and 80 revised monographs in this update, which includes the addition of doravirine, and the revision and revalidation of the monographs for baricitinib, oseltamivir, sarilumab, and tocilizumab.
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 40 new monographs and 67 revised monographs. The monographs for macrolides and taxanes have been fully revised and updated. Several new drugs have been added, including elagolix, glasdegib, istradefylline, osilodrostat, and remdesivir.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, several sections have been completely re-validated and updated, including those on eribulin, poly (ADP-ribose) polymerase inhibitors, sphingosine-1-phosphate receptor modulators, and tamoxifen.
In addition, several new drugs have been added, including avatrombopag, bempedoic acid, and volanesorsen.
There are 34 new monographs, and 49 existing monographs have been updated.
Stockley’s Drug Interactions update with new and revised monographs.
For this update, several sections have been completely re-validated and updated, including those on activated factor XA inhibitors, cranberry, dabigatran, ivacaftor and related drugs, statins, tetracyclines, and urinary antimuscarinics. In addition, 15 new tyrosine kinase inhibitors have been added. This update contains 92 new monographs, and 213 existing monographs have been updated.
Stockley’s Drug Interactions update with new and revised monographs.
This update includes the addition of letermovir, and the monographs for sugammadex have been fully revised and updated. There are 12 new monographs and 10 revised monographs in this update.
Stockley’s Drug Interactions update with new and revised monographs.
This update contains 1 new monograph and 15 revised monographs. In light of reviews by the FDA in the US about the effects of concurrent use of benzodiazepines and opioids, the relevant monographs have been partially revised and updated. The monograph on histamine has been fully revised and updated.
